Neuren Pharmaceuticals (NEU)

Shares / Stock Code


Stock Exchange / Sharemarket


Neuren Pharmaceuticals (NEU) is a biopharmaceutical company focused on the development of human therapies for neuroprotection, metabolic deficiencies and growth-related disorders. The company was formed by the merger of NeuronZ Ltd and EndocrinZ Ltd effective 1 January 2004. It has established operations in Aukland, New Zealand where majority of its employees and consultants are based. It also has an office in Australia, and Maryland in the the US. Company listed on the Australian stockmarket (ASX) on 3 February, 2005.

Neuren's has an arrangement with the Liggins Institute of the University of Auckland, under which Neuren has an ongoing right to acquire intellectual property produced by the Liggins Institute relating to neuronal repair, rescue, growth and metabolism.Major competitors include companies conducting R&D in finding cures for cancer, growth hormone deficiency and neurological disorders. Customers mainly include people of all ages who suffer from the above symptons.

NEU has three candidates: Motiva and NNZ-2566 are in clinical development to treat a range of acute and chronic neurological conditions, and NNZ-2591 is in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren Pharmaceuticals has operations in New Zealand and the United States.

Neuren Pharmaceuticals (NEU) Products and Services

  • Biopharmaceutical company with a focus on neuroprotection and metabolism.

Neuren Pharmaceuticals (NEU) Locations and Subsidiaries

Neuren Pharmaceuticals Head Office
C/o Barnes Dowell James, 122 Arthur Street,
Phone: +64 9 529 3940
Fax: +64 9 361 7981

Neuren Pharmaceuticals (NEU) Share Price

Submitted by ASX Listed Company on 14 May, 2010 - 16:49